Adagio Medical Holdings, Inc.

ADGM · NASDAQ

Adagio has pivotal VT data, FDA Breakthrough Device status, and a CE-Marked system, but no current revenue, a going-concern warning, and a cash runway that makes every regulatory milestone matter.

Follow Add to Watchlist Ask Question

NASDAQ ADGM Coverage Bootstrap Medical Devices Cardiac Electrophysiology Clinical Stage

Latest ReportMay 14, 2026Adagio Medical: the $12.9M cash clock behind a make-or-break VT filingView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

Clinical StageADGM

Clear tags

MatchAny tag All tags

Latest Thesis

Adagio Medical: the $12.9M cash clock behind a make-or-break VT filing

Adagio has pivotal VT data, FDA Breakthrough Device status, and a CE-Marked system, but no current revenue, a going-concern warning, and a cash runway that makes every regulatory milestone matter.

May 14, 2026Research reportSlides available

Read report Open slides Discussion (0)

Adagio Medical Holdings, Inc.Medical: the $12.9M cash clock behind a make-or-break VT filingMay 14, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->